XBiotech Stock (NASDAQ:XBIT)
Previous Close
$6.67
52W Range
$3.51 - $9.96
50D Avg
$7.23
200D Avg
$7.04
Market Cap
$203.32M
Avg Vol (3M)
$51.24K
Beta
1.41
Div Yield
-
XBIT Company Profile
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.
XBIT Performance
Peer Comparison
Ticker | Company |
---|---|
XFOR | X4 Pharmaceuticals, Inc. |
VECT | VectivBio Holding AG |
DAWN | Day One Biopharmaceuticals, Inc. |
EWTX | Edgewise Therapeutics, Inc. |
PHAT | Phathom Pharmaceuticals, Inc. |
STOK | Stoke Therapeutics, Inc. |
ERAS | Erasca, Inc. |
ONCT | Oncternal Therapeutics, Inc. |
GBIO | Generation Bio Co. |
TSVT | 2seventy bio, Inc. |
ABSI | Absci Corporation |
REPL | Replimune Group, Inc. |
KRON | Kronos Bio, Inc. |
PASG | Passage Bio, Inc. |
INZY | Inozyme Pharma, Inc. |
CCCC | C4 Therapeutics, Inc. |
ADVM | Adverum Biotechnologies, Inc. |
ELDN | Eledon Pharmaceuticals, Inc. |
ABOS | Acumen Pharmaceuticals, Inc. |
KZR | Kezar Life Sciences, Inc. |